ArticleKidney international reports2026
Association of FHR5 With Disease Severity in ANCA-Associated Vasculitis.
Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Alternative complement activation is pivotal in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) pathogenesis. Growing evidence highlights an important role of complement factor H (FH) in AAV. FH-related protein 5 (FHR5) functions as a competitive antagonist of FH. This study aimed to investigate the association of FHR5 with disease severity and renal outcomes in patients with AAV. Methods: In this retrospective cohort study, plasma FHR5 levels were measured using enzyme-linked immunosorbent assay in 154 patients with AAV at active stage and 55 patients in remission. Renal FHR5 deposition was assessed using immunohistochemistry (IHC) in 71 of the 154 patients. The association of plasma FHR5 levels and renal FHR5 deposition with clinicopathological parameters was analyzed. Results: Plasma levels of FHR5 were significantly higher in patients with active AAV than in those in remission and healthy controls, and correlated with increased inflammatory parameters and more severe renal damage. Positive FHR5 staining was observed in the glomeruli of 49 (69%) renal specimens. Patients with moderate or strong glomerular FHR5 deposition (grade > 1+) demonstrated significantly worse baseline renal function, more severe histopathological kidney injury, and poorer treatment response than those with negative or few deposition of FHR5 (grade ≤ 1+). Multivariable Cox regression analysis indicated that moderate or strong glomerular FHR5 deposition was independently associated with an increased risk of end-stage kidney disease (ESKD). Conclusion: Both plasma levels and glomerular deposition of FHR5 were elevated in patients with AAV and associated with more active disease and more severe renal damage. Glomerular FHR5 deposition was an independent risk factor for ESKD in AAV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.